Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 3/2012

01-03-2012 | Original article

Role of CD44 in lymphokine-activated killer cell-mediated killing of melanoma

Authors: Jingping Sun, Gabriela P. Law, Robert J. McKallip

Published in: Cancer Immunology, Immunotherapy | Issue 3/2012

Login to get access

Abstract

In the current study, we examined the potential significance of CD44 expression on lymphokine-activated killer (LAK) cells in their interaction and killing of melanoma cells. Stimulation of splenocytes with IL-2 led to a significant increase in the expression of CD44 on T cells, NK cells, and NKT cells. Treatment of melanoma-bearing CD44 WT mice with IL-2 led to a significant reduction in the local tumor growth while treatment of melanoma-bearing CD44 KO mice with IL-2 was ineffective at controlling tumor growth. Furthermore, the ability of splenocytes from IL-2-treated CD44 KO mice to kill melanoma tumor targets was significantly reduced when compared to the anti-tumor activity of splenocytes from IL-2-treated CD44 WT mice. The importance of CD44 expression on the LAK cells was further confirmed by the observation that adoptively transferred CD44 WT LAK cells were significantly more effective than CD44 KO LAK cells at controlling tumor growth in vivo. Next, the significance of the increased expression of CD44 in tumor killing was examined and showed that following stimulation with IL-2, distinct populations of cells with low (CD44lo) or elevated (CD44hi) expression of CD44 are generated and that the CD44hi cells are responsible for killing of the melanoma cells. The reduced killing activity of the CD44 KO LAK cells did not result from reduced activation or expression of effector molecules but was due, at least in part, to a reduced ability to adhere to B16F10 tumor cells.
Literature
1.
2.
go back to reference Valmori D, Scheibenbogen C, Dutoit V, Nagorsen D, Asemissen AM, Rubio-Godoy V, Rimoldi D, Guillaume P, Romero P, Schadendorf D, Lipp M, Dietrich PY, Thiel E, Cerottini JC, Lienard D, Keilholz U (2002) Circulating tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(−) effector subset exerting ex vivo tumor-specific cytolytic activity. Cancer Res 62(6):1743–1750PubMed Valmori D, Scheibenbogen C, Dutoit V, Nagorsen D, Asemissen AM, Rubio-Godoy V, Rimoldi D, Guillaume P, Romero P, Schadendorf D, Lipp M, Dietrich PY, Thiel E, Cerottini JC, Lienard D, Keilholz U (2002) Circulating tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(−) effector subset exerting ex vivo tumor-specific cytolytic activity. Cancer Res 62(6):1743–1750PubMed
3.
go back to reference Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA (2003) Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 26(4):332–342PubMedCrossRef Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA (2003) Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 26(4):332–342PubMedCrossRef
4.
go back to reference Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE (1994) Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271(12):907–913PubMedCrossRef Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE (1994) Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271(12):907–913PubMedCrossRef
5.
go back to reference Rosenberg SA, Mule JJ, Spiess PJ, Reichert CM, Schwarz SL (1985) Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med 161(5):1169–1188PubMedCrossRef Rosenberg SA, Mule JJ, Spiess PJ, Reichert CM, Schwarz SL (1985) Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med 161(5):1169–1188PubMedCrossRef
6.
go back to reference Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC (1995) Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13(3):688–696PubMed Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC (1995) Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13(3):688–696PubMed
7.
go back to reference van Weering DH, Baas PD, Bos JL (1993) A PCR-based method for the analysis of human CD44 splice products. PCR Methods Appl 3(2):100–106PubMed van Weering DH, Baas PD, Bos JL (1993) A PCR-based method for the analysis of human CD44 splice products. PCR Methods Appl 3(2):100–106PubMed
8.
9.
go back to reference Galandrini R, Albi N, Tripodi G, Zarcone D, Terenzi A, Moretta A, Grossi CE, Velardi A (1993) Antibodies to CD44 trigger effector functions of human T cell clones. J Immunol 150(10):4225–4235PubMed Galandrini R, Albi N, Tripodi G, Zarcone D, Terenzi A, Moretta A, Grossi CE, Velardi A (1993) Antibodies to CD44 trigger effector functions of human T cell clones. J Immunol 150(10):4225–4235PubMed
10.
go back to reference Tan PH, Santos EB, Rossbach HC, Sandmaier BM (1993) Enhancement of natural killer activity by an antibody to CD44. J Immunol 150(3):812–820PubMed Tan PH, Santos EB, Rossbach HC, Sandmaier BM (1993) Enhancement of natural killer activity by an antibody to CD44. J Immunol 150(3):812–820PubMed
11.
go back to reference Seth A, Gote L, Nagarkatti M, Nagarkatti PS (1991) T-cell-receptor-independent activation of cytolytic activity of cytotoxic T lymphocytes mediated through CD44 and gp90MEL-14. Proc Natl Acad Sci USA 88(17):7877–7881PubMedCrossRef Seth A, Gote L, Nagarkatti M, Nagarkatti PS (1991) T-cell-receptor-independent activation of cytolytic activity of cytotoxic T lymphocytes mediated through CD44 and gp90MEL-14. Proc Natl Acad Sci USA 88(17):7877–7881PubMedCrossRef
12.
go back to reference Hammond DM, Nagarkatti PS, Gote LR, Seth A, Hassuneh MR, Nagarkatti M (1993) Double-negative T cells from MRL-lpr/lpr mice mediate cytolytic activity when triggered through adhesion molecules and constitutively express perforin gene. J Exp Med 178(6):2225–2230PubMedCrossRef Hammond DM, Nagarkatti PS, Gote LR, Seth A, Hassuneh MR, Nagarkatti M (1993) Double-negative T cells from MRL-lpr/lpr mice mediate cytolytic activity when triggered through adhesion molecules and constitutively express perforin gene. J Exp Med 178(6):2225–2230PubMedCrossRef
13.
go back to reference Schmits R, Filmus J, Gerwin N, Senaldi G, Kiefer F, Kundig T, Wakeham A, Shahinian A, Catzavelos C, Rak J, Furlonger C, Zakarian A, Simard JJ, Ohashi PS, Paige CJ, Gutierrez-Ramos JC, Mak TW (1997) CD44 regulates hematopoietic progenitor distribution, granuloma formation, and tumorigenicity. Blood 90(6):2217–2233PubMed Schmits R, Filmus J, Gerwin N, Senaldi G, Kiefer F, Kundig T, Wakeham A, Shahinian A, Catzavelos C, Rak J, Furlonger C, Zakarian A, Simard JJ, Ohashi PS, Paige CJ, Gutierrez-Ramos JC, Mak TW (1997) CD44 regulates hematopoietic progenitor distribution, granuloma formation, and tumorigenicity. Blood 90(6):2217–2233PubMed
14.
go back to reference Rafi-Janajreh AQ, Chen D, Schmits R, Mak TW, Grayson RL, Sponenberg DP, Nagarkatti M, Nagarkatti PS (1999) Evidence for the involvement of CD44 in endothelial cell injury and induction of vascular leak syndrome by IL-2. J Immunol 163(3):1619–1627PubMed Rafi-Janajreh AQ, Chen D, Schmits R, Mak TW, Grayson RL, Sponenberg DP, Nagarkatti M, Nagarkatti PS (1999) Evidence for the involvement of CD44 in endothelial cell injury and induction of vascular leak syndrome by IL-2. J Immunol 163(3):1619–1627PubMed
15.
go back to reference McKallip RJ, Fisher M, Do Y, Szakal AK, Gunthert U, Nagarkatti PS, Nagarkatti M (2003) Targeted deletion of CD44v7 exon leads to decreased endothelial cell injury but not tumor cell killing mediated by IL-2 activated cytolytic lymphocytes. J Biol Chem 278(44):43818–43830 McKallip RJ, Fisher M, Do Y, Szakal AK, Gunthert U, Nagarkatti PS, Nagarkatti M (2003) Targeted deletion of CD44v7 exon leads to decreased endothelial cell injury but not tumor cell killing mediated by IL-2 activated cytolytic lymphocytes. J Biol Chem 278(44):43818–43830
16.
go back to reference Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3(6):1101–1108PubMedCrossRef Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3(6):1101–1108PubMedCrossRef
17.
go back to reference Wittig B, Schwarzler C, Fohr N, Gunthert U, Zoller M (1998) Curative treatment of an experimentally induced colitis by a CD44 variant V7-specific antibody. J Immunol 161(3):1069–1073PubMed Wittig B, Schwarzler C, Fohr N, Gunthert U, Zoller M (1998) Curative treatment of an experimentally induced colitis by a CD44 variant V7-specific antibody. J Immunol 161(3):1069–1073PubMed
18.
go back to reference McKallip RJ, Fisher M, Do Y, Szakal AK, Gunthert U, Nagarkatti PS, Nagarkatti M (2003) Targeted deletion of CD44v7 exon leads to decreased endothelial cell injury but not tumor cell killing mediated by interleukin-2-activated cytolytic lymphocytes. J Biol Chem 278(44):43818–43830. doi:10.1074/jbc.M304467200 PubMedCrossRef McKallip RJ, Fisher M, Do Y, Szakal AK, Gunthert U, Nagarkatti PS, Nagarkatti M (2003) Targeted deletion of CD44v7 exon leads to decreased endothelial cell injury but not tumor cell killing mediated by interleukin-2-activated cytolytic lymphocytes. J Biol Chem 278(44):43818–43830. doi:10.​1074/​jbc.​M304467200 PubMedCrossRef
19.
go back to reference Stinchcombe JC, Bossi G, Booth S, Griffiths GM (2001) The immunological synapse of CTL contains a secretory domain and membrane bridges. Immunity 15(5):751–761PubMedCrossRef Stinchcombe JC, Bossi G, Booth S, Griffiths GM (2001) The immunological synapse of CTL contains a secretory domain and membrane bridges. Immunity 15(5):751–761PubMedCrossRef
20.
go back to reference Kadison AS, Morton DL (2003) Immunotherapy of malignant melanoma. Surg Clin North Am 83(2):343–370PubMedCrossRef Kadison AS, Morton DL (2003) Immunotherapy of malignant melanoma. Surg Clin North Am 83(2):343–370PubMedCrossRef
21.
go back to reference Hershkovitz L, Schachter J, Treves AJ, Besser MJ (2010) Focus on adoptive T cell transfer trials in melanoma. Clin Dev Immunol 2010:260267. doi:10.1155/2010/260267 Hershkovitz L, Schachter J, Treves AJ, Besser MJ (2010) Focus on adoptive T cell transfer trials in melanoma. Clin Dev Immunol 2010:260267. doi:10.​1155/​2010/​260267
22.
go back to reference Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723. doi:10.1056/NEJMoa1003466 Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723. doi:10.​1056/​NEJMoa1003466
23.
go back to reference Arai S, Meagher R, Swearingen M, Myint H, Rich E, Martinson J, Klingemann H (2008) Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy 10(6):625–632. doi:10.1080/14653240802301872 PubMedCrossRef Arai S, Meagher R, Swearingen M, Myint H, Rich E, Martinson J, Klingemann H (2008) Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy 10(6):625–632. doi:10.​1080/​1465324080230187​2 PubMedCrossRef
24.
go back to reference Tam YK, Miyagawa B, Ho VC, Klingemann HG (1999) Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. J Hematother 8(3):281–290PubMedCrossRef Tam YK, Miyagawa B, Ho VC, Klingemann HG (1999) Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. J Hematother 8(3):281–290PubMedCrossRef
26.
go back to reference Fujita S, Puri RK, Yu ZX, Travis WD, Ferrans VJ (1991) An ultrastructural study of in vivo interactions between lymphocytes and endothelial cells in the pathogenesis of the vascular leak syndrome induced by interleukin-2. Cancer 68(10):2169–2174PubMedCrossRef Fujita S, Puri RK, Yu ZX, Travis WD, Ferrans VJ (1991) An ultrastructural study of in vivo interactions between lymphocytes and endothelial cells in the pathogenesis of the vascular leak syndrome induced by interleukin-2. Cancer 68(10):2169–2174PubMedCrossRef
27.
go back to reference Rafi-Janajreh AQ, Nagarkatti PS, Nagarkatti M (1998) Role of CD44 in CTL and NK cell activity. Front Biosci 3:D665–D671PubMed Rafi-Janajreh AQ, Nagarkatti PS, Nagarkatti M (1998) Role of CD44 in CTL and NK cell activity. Front Biosci 3:D665–D671PubMed
28.
go back to reference Anikeeva N, Somersalo K, Sims TN, Thomas VK, Dustin ML, Sykulev Y (2005) Distinct role of lymphocyte function-associated antigen-1 in mediating effective cytolytic activity by cytotoxic T lymphocytes. Proc Natl Acad Sci USA 102(18):6437–6442. doi:10.1073/pnas.0502467102 PubMedCrossRef Anikeeva N, Somersalo K, Sims TN, Thomas VK, Dustin ML, Sykulev Y (2005) Distinct role of lymphocyte function-associated antigen-1 in mediating effective cytolytic activity by cytotoxic T lymphocytes. Proc Natl Acad Sci USA 102(18):6437–6442. doi:10.​1073/​pnas.​0502467102 PubMedCrossRef
29.
go back to reference Somersalo K, Anikeeva N, Sims TN, Thomas VK, Strong RK, Spies T, Lebedeva T, Sykulev Y, Dustin ML (2004) Cytotoxic T lymphocytes form an antigen-independent ring junction. J Clin Invest 113(1):49–57. doi:10.1172/JCI19337 PubMed Somersalo K, Anikeeva N, Sims TN, Thomas VK, Strong RK, Spies T, Lebedeva T, Sykulev Y, Dustin ML (2004) Cytotoxic T lymphocytes form an antigen-independent ring junction. J Clin Invest 113(1):49–57. doi:10.​1172/​JCI19337 PubMed
30.
go back to reference Krensky AM, Robbins E, Springer TA, Burakoff SJ (1984) LFA-1, LFA-2, and LFA-3 antigens are involved in CTL-target conjugation. J Immunol 132(5):2180–2182PubMed Krensky AM, Robbins E, Springer TA, Burakoff SJ (1984) LFA-1, LFA-2, and LFA-3 antigens are involved in CTL-target conjugation. J Immunol 132(5):2180–2182PubMed
32.
go back to reference Davis DM, Chiu I, Fassett M, Cohen GB, Mandelboim O, Strominger JL (1999) The human natural killer cell immune synapse. Proc Natl Acad Sci USA 96(26):15062–15067PubMedCrossRef Davis DM, Chiu I, Fassett M, Cohen GB, Mandelboim O, Strominger JL (1999) The human natural killer cell immune synapse. Proc Natl Acad Sci USA 96(26):15062–15067PubMedCrossRef
33.
go back to reference Orange JS, Harris KE, Andzelm MM, Valter MM, Geha RS, Strominger JL (2003) The mature activating natural killer cell immunologic synapse is formed in distinct stages. Proc Natl Acad Sci USA 100(24):14151–14156. doi:10.1073/pnas.1835830100 PubMedCrossRef Orange JS, Harris KE, Andzelm MM, Valter MM, Geha RS, Strominger JL (2003) The mature activating natural killer cell immunologic synapse is formed in distinct stages. Proc Natl Acad Sci USA 100(24):14151–14156. doi:10.​1073/​pnas.​1835830100 PubMedCrossRef
35.
go back to reference Hegde VL, Singh NP, Nagarkatti PS, Nagarkatti M (2008) CD44 mobilization in allogeneic dendritic cell-T cell immunological synapse plays a key role in T cell activation. J Leukoc Biol 84(1):134–142. doi:10.1189/jlb.1107752 PubMedCrossRef Hegde VL, Singh NP, Nagarkatti PS, Nagarkatti M (2008) CD44 mobilization in allogeneic dendritic cell-T cell immunological synapse plays a key role in T cell activation. J Leukoc Biol 84(1):134–142. doi:10.​1189/​jlb.​1107752 PubMedCrossRef
Metadata
Title
Role of CD44 in lymphokine-activated killer cell-mediated killing of melanoma
Authors
Jingping Sun
Gabriela P. Law
Robert J. McKallip
Publication date
01-03-2012
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 3/2012
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-011-1105-4

Other articles of this Issue 3/2012

Cancer Immunology, Immunotherapy 3/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine